Spark Therapeutics: Calculating The Price Of A Cure
Executive Summary
John Furey, chief operating officer of Spark Therapeutics, discusses how the company has created a value framework for the first US-approved gene therapy to treat an incurable, inherited genetic condition: Luxturna (voretegene neparvovec-ryzl). He also highlights the remaining access and reimbursement challenges for this novel gene therapy, which is approved specifically for treatment of inherited retinal blindness from a rare RPE65 gene mutation.
You may also be interested in...
Viz.ai: Precision Targeting Of Every Patient’s Medical “Moment Of Truth”
Viz.ai is making artificial intelligence real and ready with an algorithm-based detection and diagnostics platform that is beating the clinical clock in fighting stroke. The start-up is now focused on positioning its joined-up AI software as standard-setter for broader patient engagement with big pharma on everything from participation in clinical trials to launching the next generation of high-touch specialty medicines.
Lilly's Bridge Builder, From Indiana To South Africa
Rising Leader Christopher Jon Stokes of Eli Lilly explains how some early life lessons in the restorative powers of community has guided a distinctive career path marked by engaging widely, understanding intuitively and listening actively, all in the pursuit of forging productive human connections that strive to “meet the moment” for patients.
Africa’s Geographer Of Genes
Nigerian start-up 54gene seeks to be the first private sector enterprise bent on applying Africa’s rich genetic heritage to solve the world’s most intractable diseases – ethically, without boundaries, for all.